Hyperglycemia News and Research

RSS
Hyperglycemia occurs when you have a higher than usual level of glucose in your blood. This can happen shortly after you have eaten a big meal and is not a problem if your glucose level returns to normal. Cells remove glucose from the blood in response toinsulin. If your pancreas doesn't make enough insulin, glucose can't enter the cells and remains in the blood. Blood glucose levels can also get too high if cells areunable to respond to insulin properly (insulinresistance). Without glucose, your cells are unable to make energy and can't function properly.
Clinical data from investigational study of patients with multiple myeloma presented at ASCO

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics

AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics

Drinking coffee may help prevent diabetes, report scientists

Drinking coffee may help prevent diabetes, report scientists

Additional markers of risk for diabetic microvascular complications beyond Hemoglobin A1c needed

Additional markers of risk for diabetic microvascular complications beyond Hemoglobin A1c needed

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

Value-based wellness programs for patients with metabolic syndrome

Value-based wellness programs for patients with metabolic syndrome

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Celgene reports initial data from investigator-initiated study of REVLIMID

Celgene reports initial data from investigator-initiated study of REVLIMID

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Researchers receive NIDDK grant to identify pre-diabetes symptoms

Researchers receive NIDDK grant to identify pre-diabetes symptoms

MannKind reports first-quarter net loss of $44.7 million applicable to common stockholders

MannKind reports first-quarter net loss of $44.7 million applicable to common stockholders

Study finds AFREZZA comparable to standard of care insulin therapy

Study finds AFREZZA comparable to standard of care insulin therapy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.